|
|
|
| Efficacy of Neoadjuvant Chemotherapy Combined with Surgery in Patients with Resectable and Borderline Resectable Pancreatic Cancer |
| JIANG Dongrong |
| Department of Medical Oncology, Longyan Second Hospital, Longyan Fujian 364000 |
|
|
|
|
Abstract 【Objective】 To investigate the clinical efficacy of neoadjuvant chemotherapy combined with surgery in patients with resectable and borderline resectable pancreatic cancer. 【Methods】 A total of 70 patients with pancreatic cancer were enrolled in this study. Thirty-five patients who underwent surgery alone were assigned to the control group, while 35 patients who received neoadjuvant chemotherapy followed by surgery were assigned to the observation group. Perioperative outcomes and survival rates at 1 and 3 years postoperatively were compared between the two groups. 【Results】 There were no statistically significant differences between the two groups in terms of perioperative indicators including tumor diameter, surgical procedure, operative time, postoperative hospital stay, and postoperative complications (P>0.05). The 1-year and 3-year postoperative survival rates in the observation group were significantly higher than those in the control group, and the overall survival time in the observation group was significantly longer than that in the control group (P<0.05). In addition, the overall metastasis rate and local recurrence rate after surgery in the observation group were significantly lower than those in the control group (P<0.05). 【Conclusion】 Neoadjuvant chemotherapy combined with surgery is safe and feasible for patients with resectable and borderline resectable pancreatic cancer and does not increase perioperative risks. Moreover, it can significantly improve postoperative survival rates, prolong survival time, and effectively reduce local recurrence and distant metastasis rates, demonstrating substantial clinical value.
|
|
Received: 14 August 2025
|
|
|
|
|
|
[1] PARK W, CHAWLA A, O'REILLY E M. Pancreatic cancer: a review[J].JAMA,2021, 326(9):851-862.
[2] SIEGEL R L. Global Cancer Statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021, 71(3):209-249.
[3] 中华医学会外科学分会胰腺外科学组,中国研究型医院学会胰腺疾病专业委员会. 中国胰腺癌新辅助治疗指南(2020版)[J].协和医学杂志, 2020, 11(5):547-558.
[4] BIRRER D L, GOLCHER H, CASADEI R, et al. Neoadjuvant therapy for resectable pancreatic cancer: a new standard of care pooled data from 3 randomized controlled trials[J].Ann Surg,2021, 274(5):713-720.
[5] 中华医学会外科学分会胰腺外科学组. 中国胰腺癌诊治指南(2021)[J].中华消化外科杂志, 2021, 59(7):713-729.
[6] SPRINGFELD C, FERRONE C R, KATZ M H G, et al. Neoadjuvant therapy for pancreatic cancer[J].Nat Rev Clin Oncol,2023, 20(5):318-337.
[7] LO W, ZUREIKAT A. Neoadjuvant therapy in pancreatic cancer: a review and update on recent trials[J].Curr Opin Gastroenterol,2022, 38(5):521-531.
[8] ZHOU B, ZHANG S R, CHEN G, et al. Developments and challenges in neoadjuvant therapy for locally advanced pancreatic cancer[J].World J Gastroenterol,2023, 29(35):5094-5103.
[9] VAN DAM J L, JANSSEN Q P, BESSELINK M G, et al. Neoadjuvant therapy or upfront surgery for resectable and borderline resectable pancreatic cancer: a meta-analysis of randomised controlled trials[J].Eur J Cancer,2022, 160(1):140-149.
[10] ALISEDA D, MARTí-CRUCHAGA P, ZOZAYA G, et al. Neoadjuvant therapy versus upfront surgery in resectable pancreatic cancer: reconstructed patient-level meta-analysis of randomized clinical trials[J].BJS Open,2024, 8(5):zrae087.
[11] AUGUSTINUS S, SCHAFRAT P J M, JANSSEN B V, et al. Nationwide impact of centralization, neoadjuvant therapy, minimally invasive surgery, and standardized pathology reporting on R0 resection and overall survival in pancreatoduodenectomy for pancreatic cancer[J].Ann Surg Oncol,2023, 30(8):5051-5060.
[12] BAI X L, LI X, CHEN Y W, et al. Neoadjuvant nab-paclitaxel plus gemcitabine followed by modified FOLFIRINOX for resectable pancreatic cancer: a randomized phase 3 trial[J].Cancer Cell,2025, 43(12):2259-2267. |
|
|
|
2026, Vol. 43 
